Introduction Due to the importance of lung cancer early treatment because of its severity and
extent worldwide a systematic literature review was conducted about the impact of delays in …

ABSTRACT Background: The SARS-CoV-2 pandemic introduced a global distraction effect
in cancer patients' care. The aim of this study was to explore the effect of the pandemic on …

This European Respiratory Society guideline is dedicated to the provision of good quality
recommendations in lung cancer care. All the clinical recommendations contained were …

Introduction Patients with non–small-cell lung cancer (NSCLC) whose tumors harbor
anaplastic lymphoma kinase (ALK) rearrangements can be treated with ALK tyrosine kinase …

Background Advanced lung cancer patients exposed to breakthrough therapies like EGFR
tyrosine kinase inhibitors (EGFR‐TKI) may experience social inequalities in survival, partly …

OBJECTIVES: Patient assistance programs (eg, co-pay assistance) may reduce patients' out-
of-pocket costs for prescription medicines, providing financial assistance to access …

BACKGROUND: Barriers to accessing oral oncolytic therapy include insurance prior
authorization, high copays, and limited distribution drug networks. These barriers increase …

Introduction We assessed the proportion of patients with advanced epidermal growth factor
receptor (EGFR) and anaplastic lymphoma kinase (ALK) positive non–small-cell lung cancer …

Background Molecular testing is critical to guiding treatment approaches in patients with
metastatic non‐small cell lung cancer (mNSCLC), with testing delays adversely impacting …

Aims To assess US payers' per-patient cost of testing associated with next-generation
sequencing (NGS) versus polymerase chain reaction (PCR) biomarker testing strategies …